Xdynia Receives $50k Investment from CIT GAP Funds

Xdynia LLC, a Charlottesville, Va.-based drug development company, has received a $50k investment from the Center for Innovative Technology’s GAP Funds (http://www.citgapfunds.org).

Led by President Yuri Maricich Xdynia is developing a new class of compounds targeting the Cav 3.2 Ca++ channel, a common pathway in the development of neuropathic pain. These inhibitors are designed to alleviate common side-effects related to current pain therapies (nausea, vomiting, constipation, dizziness, and somnolence) with well-tolerated, non-addictive treatments.

Xdynia intends to use the funds to advance its product to pre-clinical trials and produce the data necessary to begin the commercialization of a Cav3.2 product for the treatment of pain.



Join the discussion